CD274 Proteïne (C-muis IgG1-Fc, menselijk)

CD274

B7-H, B7-H1, B7H1, hPD-L1, PD-L1, PDCD1L1, PDCD1LG1, PDL1

C-mouse IgG1-Fc

< 1.0 EU per μg protein as determined by the LAL method.

≥ 95 % as determined by SDS-PAGE. ≥ 85 % as determined by SEC-HPLC.

1. Measured by its binding ability in a functional ELISA. Immobilized recombinant Human PD1-His (Cat:10377-H08H) at 10 μg/ml (100 μl/well) can bind human PD-L1 (Cat:10084-H05H) with a linear range of 1.28-20 μg/ml. 2. Labeled biotin to PD-L1 Protein, Human, Recombinant (ECD, Fc Tag) by a certain molar ratio; Using the Octet RED System, the affinity constant (Kd) of PD-L1 Protein, Human, Recombinant (ECD, Fc Tag), Biotinylated (Cat. 10084-H05H-B) bound to Atezolizumab was 0.1 nM. 3. CHO cells were transduced with human PD1 and subjected to flow cytometric analysis using recombinant human PDL1 protein (mouse IgG2a Fc tag) (left, Cat. No. 10084-H05H, red) and a negative control protein (blue) . The cells were then stained with an FITC-conjugated anti-mouse IgG2a Fc antibody. Non-transduced CHO cells were used as a control (right) . 4.Immobilized Recombinant Human PD-L1/B7-H1 Protein (ECD, mFc Tag), HPLC-verified (Cat: 10084-H05H) at 2 μg/mL (100 μL/well) can bind Recombinant Human PD-1 Protein (ECD, hFc Tag), HPLC-verified (Cat: 10377-H02H) the EC50 is 67-201 ng/mL. 5.Serial dilutions of Nivolumab were added into Recombinant Human PD-L1 / B7-H1 / CD274 Protein (ECD, mFc Tag) (Catalog# 10084-H05H), the Nivolumab derived Anti-PD1 Antibody, Human IgG4 can block the binding of 20 μg/mL of Recombinant Human PD-1 Protein (ECD, hFc & AVI Tag), Biotinylated, HPLC-verified (Catalog# 10377-H41H-B) to Recombinant Human PD-L1 / B7-H1 / CD274 Protein (ECD, mFc Tag), the IC50 is 278.7 ng/mL (Routinely tested) .

Met1-Thr239

The recombinant human CD274 consists of 455 amino acids and predicts a molecular mass of 51.7 kDa. As a result of glycosylation, the human CD274 migrates as an approximately 66 kDa protein in SDS-PAGE under reducing conditions.

Human